ANTONAZZO IPPAZIO COSIMO

Ferrara, P., Antonazzo, I., Zamparini, M., Fornari, C., Borrelli, C., Boarino, S., et al. (2024). Epidemiology of SLE in Italy: an observational study using a primary care database. LUPUS SCIENCE & MEDICINE, 11(1) [10.1136/lupus-2024-001162]. Detail

Losa, L., Antonazzo, I., Di Martino, G., Mazzaglia, G., Tafuri, S., Mantovani, L., et al. (2024). Immunogenicity of Recombinant Zoster Vaccine: A Systematic Review, Meta-Analysis, and Meta-Regression. VACCINES, 12(5) [10.3390/vaccines12050527]. Detail

Brauer, M., Roth, G., Aravkin, A., Zheng, P., Abate, K., Abate, Y., et al. (2024). Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. THE LANCET, 403(10440 (18–24 May 2024)), 2162-2203 [10.1016/s0140-6736(24)00933-4]. Detail

Antonazzo, I., Cortesi, P., Zanon, E., Pasca, S., Morfini, M., Santoro, C., et al. (2024). Personalized Prophylaxis with myPKFiTCE: A Real-World Cost-Effectiveness Analysis in Haemophilia A Patients. MEDICINA, 60(1) [10.3390/medicina60010034]. Detail

Cortesi, P., Antonazzo, I., Palladino, P., Gnesi, M., Mele, S., D’Amelio, M., et al. (2024). Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis. ACTA DIABETOLOGICA [10.1007/s00592-024-02276-3]. Detail